The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation

Oncogene

Volumn 35, Issue 10, 2016, Pages 1314-1323

  Chen, C C ^a   Kim, K H ^a   Lau, L F ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; CYSTEINE RICH PROTEIN 61; DIETHYLNITROSAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; REACTIVE OXYGEN METABOLITE; VERY LATE ACTIVATION ANTIGEN 6; EGFR PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOGENESIS; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER TUMOR; MALE; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE-RICH PROTEIN 61; DIETHYLNITROSAMINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84960795541     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.190     Document Type: Article

References (56)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458.
2. Centers for Disease Control and Prevention (CDC), Hepatocellular carcinoma-United States, 2001-2006 MMWR Morb Mortal Wkly Rep 2010; 59: 517-520
3. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694-698.
4. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-Alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391.
5. Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 2011; 10: 945-963.
6. Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, Lau LF. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002; 22: 8709-8720.
7. Mo F-E, Lau LF. The matricellular protein CCN1 is essential for cardiac development. Circ Res 2006; 99: 961-969.
8. Jun JI, Lau LF. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol 2010; 12: 676-685.
9. Choi JS, Kim KH, Lau LF. The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol 2015; 8: 1285-1296.
10. Kim KH, Chen CC, Monzon RI, Lau LF. The matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. Mol Cell Biol 2013; 33: 2078-2090.
11. Kim KH, Chen C-C, Alpini G, Lau LF. CCN1 induces ductular reaction through integrin avb5-mediated NF?B activation. J Clin Invest 2015; 125: 1886-1900.
12. Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the Hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011; 71: 2728-2738.
13. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 2002; 21: 8178-8185.
14. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005; 11: 7243-7254.
15. Haque I, Mehta S, Majumder M, Dhar K, De A, McGregor D, et al. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer 2011; 10: 8.
16. Xie D, Yin D, Tong X, O'Kelly J, Mori A, Miller C, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 2004; 64: 1987-1996.
17. Tong X, Xie D, O'Kelly J, Miller CW, Muller-Tidow C, Koeffler HP. Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem 2001; 276: 47709-47714.
18. Chien W, Kumagai T, Miller CW, Desmond JC, Frank JM, Said JW, et al. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 2004; 279: 53087-53096.
19. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, product of a growth factorinducible immediate-Early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998; 95: 6355-6360.
20. Todorovic V, Chen C-C, Hay N, Lau LF. The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J Cell Biol 2005; 171: 559-568.
21. Chen C-C, Young JL, Monzon RI, Chen N, Todorovic V, Lau LF. Cytotoxicity of TNFa is regulated by Integrin-Mediated Matrix Signaling. EMBO J 2007; 26: 1257-1267.
22. Feng P, Wang B, Ren EC. Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. Int J Biochem Cell Biol 2008; 40: 98-109.
23. Li ZQ, Ding W, Sun SJ, Li J, Pan J, Zhao C, et al. Cyr61/CCN1 is regulated by Wnt/ beta-catenin signaling and plays an important role in the progression of hepatocellular carcinoma. PLoS ONE 2012; 7: e35754.
24. Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol 2013; 7: 206-223.
25. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-1311.
26. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
27. Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, et al. Hepatitis B vs hepatitis C infection on viral hepatitis-Associated hepatocellular carcinoma. BMC Gastroenterol 2012; 12: 64.
28. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-Driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-990.
29. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13: 1929-1939.
30. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-947.
31. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 2009; 15: 85-94.
32. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010; 70: 10202-10212.
33. Kang JS, Wanibuchi H, Morimura K, Gonzalez FJ, Fukushima S. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res 2007; 67: 11141-11146.
34. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-Adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996; 71: 57-81.
35. Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury-And deathinduced inflammation. Immunity 2011; 35: 467-477.
36. Juric V, Chen CC, Lau LF. Fas-mediated apoptosis is regulated by the extracellular matrix protein CCN1 (CYR61) in vitro and in vivo. Mol Cell Biol 2009; 29: 3266-3279.
37. Chen N, Leu S-J, Todorovic V, Lam SCT, Lau LF. Identification of a novel integrin avb3 binding site in CCN1 (CYR61) critical for pro-Angiogenic activities in vascular endothelial cells. J Biol Chem 2004; 279: 44166-44176.
38. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006; 209: 13-20.
39. Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, Rath M, et al. c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev 2006; 20: 2306-2314.
40. Dumaz N, Meek DW. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 1999; 18: 7002-7010.
41. She QB, Chen N, Dong Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 2000; 275: 20444-20449.
42. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
43. Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med 2013; 7: 242-254.
44. Liebermann DA, Hoffman B, Vesely D. p53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle 2007; 6: 166-170.
45. Teoh N, Pyakurel P, Dan YY, Swisshelm K, Hou J, Mitchell C, et al. Induction of p53 renders ATM-Deficient mice refractory to hepatocarcinogenesis. Gastroenterology 2010; 138: 1155-1165.
46. Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, Seki E, et al. p38alpha inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res 2013; 73: 215-224.
47. Mellert H, Espinosa JM. Tumor suppression by p53: is apoptosis important or not?. Cell Rep 2013; 3: 1335-1336.
48. Kardeh S, Ashkani-Esfahani S, Alizadeh AM. Paradoxical action of reactive oxygen species in creation and therapy of cancer. Eur J Pharmacol 2014; 735: 150-168.
49. Juric V, Chen CC, Lau LF. Fas-mediated apoptosis is regulated by the extracellular matrix protein CCN1 (CYR61) in vitro and in vivo. Mol Cell Biol 2009; 29: 3266-3279.
50. Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu J, et al. DNA damage-induced sustained p53 activation contributes to inflammation-Associated hepatocarcinogenesis in rats. Oncogene 2013; 32: 4565-4571.
51. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
52. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-1067.
53. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005; 41: 307-314.
54. Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 2014; 59: 1577-1590.
55. Smith NF, Baker SD, Gonzalez FJ, Harris JW, Figg WD, Sparreboom A. Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br J Cancer 2008; 98: 1630-1632.
56. Li WC, Ralphs KL, Tosh Ds. Isolation and culture of adult mouse hepatocytes. Methods Mol Biol 2010; 633: 185-196.